

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 May 2001 (31.05.2001)

PCT

(10) International Publication Number
WO 01/37873 A3

- (51) International Patent Classification⁷: **A61K 39/395**, C07K 1/22, A61P 31/00, 35/00, 37/00 // C07K 16/28, 14/715
- (21) International Application Number: PCT/US00/42090
- (22) International Filing Date:
10 November 2000 (10.11.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/164,695 10 November 1999 (10.11.1999) US
- (71) Applicant and
(72) Inventor: **LENTZ, M., Rigdon** [US/US]; 6347 Shadow Ridge Court, Brentwood, TN 37027 (US).
- (74) Agents: **PABST, Patrea, L.** et al.; Holland & Knight LLP, One Atlantic Center, Suite 2000, 1201 West Peachtree Street, N.E., Atlanta, GA 30309-3400 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- (88) Date of publication of the international search report:
7 March 2002
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 01/37873 A3

(54) Title: METHOD AND SYSTEM TO REMOVE CYTOKINE INHIBITOR IN PATIENTS

(57) Abstract: A method to treat disorders characterized by production of soluble cytokine receptor molecules, e.g. soluble tumor necrosis factor receptors (sTNFR). Said diseases comprise many types of cancer and certain diseases such as HIV-infection. In the preferred embodiment, the patient's blood is passed through a column having antibodies immobilized thereon, which bind to and remove the sTNRF molecules, and then led back into the patient, according to the UltraPheresis (TM) method. The process can be performed alone or in combination with other therapies, e.g. administration of anti-angiogenic compounds, procoagulant compounds, cytokines, chemotherapeutic agents or by radiation.

INTERNATIONAL SEARCH REPORT

In: International Application No
PCT/US 00/42090

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K39/395 C07K1/22 A61P31/00 A61P35/00 A61P37/00
 //C07K16/28,C07K14/715

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 C07K A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EMBASE, WPI Data, PAJ, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	C. SELINSKY ET AL.: "Multifaceted inhibition of anti-tumour immune mechanisms by soluble tumour necrosis factor receptor type I." IMMUNOLOGY, vol. 94, no. 1, May 1998 (1998-05), pages 88-93, XP002172135 Oxford, GB abstract page 88, left-hand column, line 1 - line 14 page 91, right-hand column, line 32 -page 92, left-hand column, line 10 --- -/--	1-16

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

24 July 2001

Date of mailing of the international search report

06/08/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Nooij, F

INTERNATIONAL SEARCH REPORT

In International Application No
PCT/US 00/42090

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	M. LENTZ: "The role of therapeutic apheresis in the treatment of cancer: a review." THERAPEUTIC APHERESIS, vol. 3, no. 1, February 1999 (1999-02), pages 40-49, XP001010150 USA the whole document	1-16
A	M. LENTZ: "Continuous whole blood UltraPheresis procedure in patients with metastatic cancer." JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS, vol. 8, no. 5, October 1989 (1989-10), pages 511-527, XP001010099 New York, NY, USA abstract figures 1,2	1-16
A	T. GATANAGA ET AL.: "Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients." PROCEEDINGS OF THE NATIONAL ACADEMY OF THE U.S.A., vol. 87, no. 22, November 1990 (1990-11), pages 8781-8784, XP002172137 Washington, DC, USA abstract	1-16
A	US 4 708 713 A (LENTZ) 24 November 1987 (1987-11-24) figure 1 claims	1-16
A	C. TETTA ET AL.: "Continuous plasma filtration coupled with sorbents." KIDNEY INTERNATIONAL, vol. 53, no. suppl. 66, May 1998 (1998-05), pages S186-S189, XP001010123 New York, NY, USA abstract figure 1	1-16
P,X	WO 99 61085 A (M. LENTZ) 2 December 1999 (1999-12-02) the whole document	1-16

INTERNATIONAL SEARCH REPORT

Information on patent family members

In International Application No
PCT/US 00/42090

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4708713 A	24-11-1987	AT 88097 T	15-04-1993
		AU 596567 B	10-05-1990
		AU 4992985 A	22-05-1986
		CA 1262681 A	07-11-1989
		DE 3587266 A	19-05-1993
		DE 3587266 T	29-07-1993
		EP 0184040 A	11-06-1986
		JP 61172563 A	04-08-1986
		MX 168132 B	06-05-1993
		ZA 8508676 A	30-07-1986
WO 9961085 A	02-12-1999	AU 4542599 A	13-12-1999
		EP 1079875 A	07-03-2001
		US 6231536 B	15-05-2001